AEGLEA BIOTHERAPEUTICS INC's ticker is AGLE and the CUSIP is 00773J103. A total of 78 filers reported holding AEGLEA BIOTHERAPEUTICS INC in Q2 2019. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2022 | $113,000 | -55.9% | 48,918 | -9.3% | 0.00% | – |
Q4 2021 | $256,000 | -40.5% | 53,918 | -0.4% | 0.00% | -100.0% |
Q3 2021 | $430,000 | +17.2% | 54,143 | +2.8% | 0.00% | – |
Q2 2021 | $367,000 | 0.0% | 52,667 | +13.7% | 0.00% | – |
Q1 2021 | $367,000 | -6.1% | 46,332 | -6.8% | 0.00% | -100.0% |
Q4 2020 | $391,000 | +21.8% | 49,702 | +9.7% | 0.00% | 0.0% |
Q3 2020 | $321,000 | -32.7% | 45,327 | -12.0% | 0.00% | 0.0% |
Q2 2020 | $477,000 | +169.5% | 51,527 | +35.8% | 0.00% | – |
Q1 2020 | $177,000 | -38.1% | 37,952 | +1.3% | 0.00% | – |
Q4 2019 | $286,000 | -0.3% | 37,482 | +0.5% | 0.00% | -100.0% |
Q3 2019 | $287,000 | +22.1% | 37,311 | +8.5% | 0.00% | – |
Q2 2019 | $235,000 | +21.1% | 34,378 | +42.5% | 0.00% | – |
Q1 2019 | $194,000 | +19.8% | 24,130 | +11.9% | 0.00% | – |
Q4 2018 | $162,000 | +16.5% | 21,571 | +48.7% | 0.00% | – |
Q3 2018 | $139,000 | -13.7% | 14,502 | -4.8% | 0.00% | – |
Q2 2018 | $161,000 | – | 15,233 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO | 279,678 | $2,587,000 | 10.00% |
Aisling Capital Management LP | 1,691,151 | $15,643,000 | 5.97% |
Samsara BioCapital, LLC | 967,500 | $8,949,000 | 2.88% |
Bain Capital Life Sciences Investors, LLC | 2,700,000 | $24,975,000 | 2.62% |
Soleus Capital Management, L.P. | 369,852 | $3,421,000 | 1.95% |
Nantahala Capital Management | 3,204,830 | $29,645,000 | 0.89% |
Lion Point Capital, LP | 300,000 | $2,775,000 | 0.67% |
Abingworth LLP | 240,500 | $2,221,000 | 0.62% |
Sio Capital Management, LLC | 211,104 | $1,953,000 | 0.57% |
Orbimed Advisors | 4,015,524 | $37,144,000 | 0.52% |